Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in macrophage activation syndrome associated with sJIA, AOSD, or SLE
NL-OMON59578Phase 3Completed
- Sponsor
- Sobi
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of emapalumab in macrophage activation syndrome (MAS) (2 cohorts), sponsored by Sobi. Primary endpoint: Complete response at Week 8. Started Sep 2022; status: completed.
02
Drugs
emapalumab
03
Conditions
macrophage activation syndrome (MAS)
Beyond the preview
Go deeper on NL-OMON59578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59578.